Monday, March 18, 2019 - The advances in Artificial intelligence (AI) have successfully propagated into the many areas such as computer vision, speech recognition, and natural language processing. AI is now rapidly propagating into the areas requiring substantial domain expertise such as biology, chemistry promising to speed up, improving the success rates, and lower the cost of drug discovery and drug development.
The laboratories of Jianfeng Pei at Peking University and Alex Zhavoronkov at Insilico Medicine partner with Frontiers in Pharmacology, a leading open science platform on the research topic "AI for drug discovery and development". This Research Topic will highlight the most recent advances and perspectives of all kinds of artificial intelligence technologies used to accelerate and improve pharmaceutical R&D.
"Artificial intelligence is rapidly propagating into life sciences resulting in a wave of academic publications in the field of AI-powered drug discovery, a plethora of startups developing new strategies and pursuing innovative business models to transform pharmaceutical research and development. The pharmaceutical industry is also strengthening its internal capabilities in this area by centralizing the previously segregated data sources, hiring data scientists and investing in infrastructure," said Jianfeng Pei, Ph.D., Peking University, Beijing.
"The integration of machine learning with ever-more extensive biological data-sets promises to accelerate advancement in the field of human health in an unprecedented manner, not least to assist in tackling the 'failure to fail' in current drug development pipelines, previously highlighted by our Translational Pharmacology section Chief Editor Prof Alastair Stewart. We in Frontiers in Pharmacology are excited to partner with Dr. Zhavoronkov and Dr. Pei, to develop a broad-scope, open-access article collection aiming to reflect and catalyze leading-edge developments in this field globally," said Brian Boyle, Journal Development Manager, Frontiers in Pharmacology Journal.
The applications of AI in drug discovery are very broad and can be classified into several areas:
- 1. Knowledge discovery and hypothesis generation
2. Target identification
3. Compound generation
4. Virtual screening
6. Predicting the outcomes of clinical trials and clinical trials enrollment
7. Personalized medicine
8. Real-world evidence analysis and actuarial pharmacology
The advent of artificial intelligence in the pharmaceutical industry is expected to enable the countries that did not previously engage in early-stage drug discovery and innovative medicine to leapfrog years of pharma R&D and contribute to the global push for better health. With 1.4 billion people and the government push for innovative medicines, China is expected to become the major force in the pharmaceutical industry. The authors hope that trade wars do not impact this important field. Cancer, Alzheimer's and other diseases do not discriminate by the nation. Until there is a clear set of cures, a trade war in biotechnology R&D is equivalent to a war on all people. Advances in biomedicine require massive international collaborations, diversity, and data sharing initiatives.
"We are very happy to partner with the leading scientist in China and globally, Dr. Jianfeng Pei of the Peking University on this research topic and welcome scientists from all over the world to collaborate and contribute to it", said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The Research Topic covers new AI algorithms and (or) applications in a wide range of areas such as drug target identification, systems biology, pharmacogenomics, network pharmacology, chemical property prediction, synthesis planning, molecular design and generation, protein-ligand interaction, drug-target interaction network, drug-related knowledge graphs, big data analysis for drug information, and image recognition. This Research Topic will highlight the most recent advances and perspectives on all kinds of artificial intelligence technologies used in drug design.
In this Research Topic, the authors welcome Perspective and Policy papers proposing the paths for the development of innovative medicines using AI and accelerating pharma R&D in the developed and developing countries.
About Frontiers Research Topics
Frontiers' Research Topics are peer-reviewed article collections around themes of cutting-edge research. Defined, managed, and led by renowned researchers, they unite the world's leading experts around the hottest topics in research, stimulating collaboration and accelerating science.
Managed and disseminated on Frontiers' customized Open Science platform, these collections are free to access and highly visible, increasing the discoverability, readership, and citations of your research.
Research Topics spotlight the most specialized communities and enable leading researchers to edit article collections Over 200,000 authors contributed to Research Topics
Research Topic articles have received more than 280,000,000 views and downloads
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/